Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISM4808 in healthy adult subjects
NCT07415304Phase 1Not yet recruiting
- Sponsor
- TaiGen Biotechnology Co., Ltd.
- Start
- Feb 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of ISM4808 in anemia, sponsored by TaiGen Biotechnology Co., Ltd. Primary endpoint: Number of Participants With treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at Day 18. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ISM4808
03
Conditions
anemia
Beyond the preview
Go deeper on NCT07415304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415304.